AIDX Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -63.3%, SMA50 -63.3%, SMA200 -63.3%). The stock remains hovering near 52-week lows, trading -91.84% below its high and over -21.84% above its low. Average 10-day trading volume of 1.39 million shares is significantly above the 3-month average of 367.62 thousand, indicating heightened recent market interest.

20/20 Biolabs, Inc. Common Stock has 10.48 million shares outstanding. The public float is 9.02 million shares, elevated short interest at 0.39% of float. This equals 33.12 thousand shares. The short ratio is 0.48 days.

20/20 Biolabs, Inc. Common Stock generated EPS of $nan over the past year. Five-year average earnings growth is -17.86%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.00 to $5.00. The high target offers 410.2% upside. The low target suggests 410.2% downside. The mean target is $5.00. This offers 410.2% upside. 20/20 Biolabs, Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended May 20, 2026, missed forecasts by 180.0%.

currently trading near 52-week highs band. Valuation shows 20/20 Biolabs, Inc. Common Stock trading at a premium to the broader market with a P/E of -1.79. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $5.00, suggesting 410.2% upside. Our AI forecast model points to short-term weakness (-9.18% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-26.53% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that 20/20 Biolabs, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -9.18%, with price expected at $0.89 by June 05, 2026, within a range of $0.82 to $0.96 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by August 20, 2026, with a range of $0.00 to $0.02. 1-Year Outlook: Projected loss of -26.53%, with price at $0.72 by May 21, 2027, within a range of $0.00 to $0.00.

20/20 Biolabs, Inc. Common Stock (NASDAQ:AIDX) closed at $0.98 USD, losing -$0.23 (-18.67%) from the previous close of $1.21. The stock is currently mid-range between its 52-week high and low $0.90 and $50.00. With a market capitalization of about $5.53 million, 20/20 Biolabs, Inc. Common Stock is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.42). Key stats such as the average daily volume over the past year has been around 360.41 thousand shares, trading with heavier-than-usual volume. Headquartered in Gaithersburg, MD, 20/20 Biolabs, Inc. Common Stock operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Jonathan Cohen, the company employs approximately 13 people and listed since June 15, 2023. 20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

20/20 Biolabs, Inc. Common Stock trades at a P/E ratio of -1.79, slightly below the S&P 500 average, with a price-to-sales ratio of 4.23 and a price-to-book ratio of 2.94 suggesting the stock is closer to book value. The P/FCF stands at -3.03, also above market averages.